• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

诱导化疗与单纯同步放化疗治疗局部晚期喉和下咽鳞状细胞癌患者时的功能性喉保留情况

Functional Larynx Preservation in Patients With Locally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx Treated With Induction Chemotherapy vs. Concurrent Chemoradiation Alone.

作者信息

Nehlsen Anthony D, Lehrer Eric J, Dickstein Daniel R, Posner Marshall R, Misiukiewicz Krzysztof, Liu Jerry, Gupta Vishal, Bakst Richard L, Sharma Sonam

机构信息

Radiation Oncology, Mount Sinai, New York, USA.

Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York City, USA.

出版信息

Cureus. 2021 Jul 11;13(7):e16310. doi: 10.7759/cureus.16310. eCollection 2021 Jul.

DOI:10.7759/cureus.16310
PMID:34405069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8354511/
Abstract

Objectives Chemoradiation therapy (CRT) has been established as a standard treatment for locally advanced hypopharynx/larynx squamous cell carcinoma (SCC) but the role of induction chemotherapy (IC) remains unclear. The primary outcome of this study is to determine whether functional larynx-preservation survival (FLPS) is improved with the addition of IC in these patients. Secondary outcomes were overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and laryngectomy rates. Methods Records for patients with AJCC 8th edition clinical stage III-IVB laryngeal and hypopharyngeal SCC treated with CRT +/- IC from 2005-2019 were reviewed. FLPS was defined as time until death, progression, laryngectomy, or non-functional larynx. Kaplan-Meier curves were generated for FLPS, OS, PFS, and DMFS. Outcomes were compared using the stratified log-rank test. Laryngectomy rates were compared using Fisher's exact test. Results We included 52 patients with laryngeal and 38 with hypopharyngeal SCC (n=90); 19 patients with laryngeal SCC and 19 with hypopharyngeal SCC received IC (median three cycles). There were no differences in the three-year FLPS (61% vs 67.8%; p=0.88), OS (73.9% vs 86.2%; p=0.42), PFS (53.6% vs 62.6%; p=0.44), or DMFS (65.2% vs 71.5%, p= 0.85) between patients who did and did not receive IC all patients. Laryngectomy rates did not differ with and without IC (18.4 % vs 7.7%; p=0.19). Conclusion In this study of advanced laryngeal and hypopharyngeal SCC, IC did not improve three-year FLPS, OS, PFS, or laryngectomy rates compared to CRT alone. A large prospective series would provide a more robust understanding of the role of IC in this group of patients.

摘要

目的 放化疗(CRT)已被确立为局部晚期下咽/喉鳞状细胞癌(SCC)的标准治疗方法,但诱导化疗(IC)的作用仍不明确。本研究的主要结果是确定在这些患者中添加IC是否能提高功能性保喉生存率(FLPS)。次要结果包括总生存期(OS)、无进展生存期(PFS)、无远处转移生存期(DMFS)和喉切除术率。方法 回顾了2005年至2019年接受CRT±IC治疗的AJCC第8版临床III-IVB期喉和下咽SCC患者的记录。FLPS定义为直至死亡、进展、喉切除术或无功能喉的时间。生成FLPS、OS、PFS和DMFS的Kaplan-Meier曲线。使用分层对数秩检验比较结果。使用Fisher精确检验比较喉切除术率。结果 我们纳入了52例喉SCC患者和38例下咽SCC患者(n=90);19例喉SCC患者和19例下咽SCC患者接受了IC(中位三个周期)。接受和未接受IC的所有患者在三年FLPS(61%对67.8%;p=0.88)、OS(73.9%对86.2%;p=0.42)、PFS(53.6%对62.6%;p=0.44)或DMFS(65.2%对71.5%,p=0.85)方面没有差异。有无IC的喉切除术率没有差异(18.4%对7.7%;p=0.19)。结论 在这项晚期喉和下咽SCC的研究中,与单独使用CRT相比,IC并未提高三年FLPS、OS、PFS或喉切除术率。一个大型前瞻性系列研究将更有力地了解IC在这组患者中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778a/8354511/9ad0b50bde58/cureus-0013-00000016310-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778a/8354511/04be2e7af05c/cureus-0013-00000016310-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778a/8354511/e32c7b9cdf77/cureus-0013-00000016310-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778a/8354511/25fa9728f649/cureus-0013-00000016310-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778a/8354511/9ad0b50bde58/cureus-0013-00000016310-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778a/8354511/04be2e7af05c/cureus-0013-00000016310-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778a/8354511/e32c7b9cdf77/cureus-0013-00000016310-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778a/8354511/25fa9728f649/cureus-0013-00000016310-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/778a/8354511/9ad0b50bde58/cureus-0013-00000016310-i04.jpg

相似文献

1
Functional Larynx Preservation in Patients With Locally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx Treated With Induction Chemotherapy vs. Concurrent Chemoradiation Alone.诱导化疗与单纯同步放化疗治疗局部晚期喉和下咽鳞状细胞癌患者时的功能性喉保留情况
Cureus. 2021 Jul 11;13(7):e16310. doi: 10.7759/cureus.16310. eCollection 2021 Jul.
2
Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: efficacy in laryngeal preservation for advanced hypopharyngeal and laryngeal squamous cell carcinoma.回顾性评估新辅助卡瑞利珠单抗联合诱导化疗:在晚期下咽及喉鳞状细胞癌保喉中的疗效。
Cancer Immunol Immunother. 2024 Feb 15;73(3):54. doi: 10.1007/s00262-023-03579-0.
3
PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study.PD-1 抑制剂联合紫杉醇(白蛋白结合型)和顺铂用于局部晚期喉和声门下鳞状细胞癌的喉保留:一项回顾性研究。
Cancer Immunol Immunother. 2023 Dec;72(12):4161-4168. doi: 10.1007/s00262-023-03550-z. Epub 2023 Oct 7.
4
A 10-Year Study on Larynx Preservation Compared With Surgical Resection in Patients With Locally Advanced Laryngeal and Hypopharyngeal Cancers.一项关于局部晚期喉癌和下咽癌患者喉保留与手术切除对比的10年研究。
Front Oncol. 2020 Oct 15;10:535893. doi: 10.3389/fonc.2020.535893. eCollection 2020.
5
Induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancer: Single institution experience.局部晚期喉癌和下咽癌的诱导化疗:单机构经验
Head Neck. 2020 Nov;42(11):3118-3124. doi: 10.1002/hed.26353. Epub 2020 Jul 16.
6
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.晚期喉癌诱导化疗后行放疗或放化疗时的器官保存及治疗毒性
Am J Clin Oncol. 2005 Aug;28(4):371-8. doi: 10.1097/01.coc.0000162423.13431.8d.
7
Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial.诱导 TPF 后同期放化疗与单纯同期放化疗治疗局部晚期下咽癌的初步随机 2 期试验分析。
BMC Cancer. 2022 Nov 29;22(1):1235. doi: 10.1186/s12885-022-10306-y.
8
Laryngeal Preservation Strategies in Locally Advanced Laryngeal and Hypopharyngeal Cancers.局部晚期喉癌和下咽癌的喉功能保留策略
Front Oncol. 2019 May 31;9:419. doi: 10.3389/fonc.2019.00419. eCollection 2019.
9
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.诱导化疗联合顺铂、5-氟尿嘧啶、±多西他赛用于喉保留的多中心随机 III 期试验的长期结果。
J Natl Cancer Inst. 2015 Dec 16;108(4). doi: 10.1093/jnci/djv368. Print 2016 Apr.
10
Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors.基于诱导化疗的局部晚期下咽癌喉保留方案:肿瘤学和功能结局及预后因素
Eur Arch Otorhinolaryngol. 2016 Oct;273(10):3299-306. doi: 10.1007/s00405-016-3919-3. Epub 2016 Feb 9.

引用本文的文献

1
Clinical and Therapeutic Considerations for Older Adults with Head and Neck Cancer.老年头颈部癌症患者的临床和治疗注意事项。
Clin Interv Aging. 2023 Mar 17;18:409-422. doi: 10.2147/CIA.S366155. eCollection 2023.
2
[Study on the indication of concurrent chemoradiotherapy for locally advanced laryngeal carcinoma].[局部晚期喉癌同步放化疗适应证的研究]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Sep;36(9):721-725. doi: 10.13201/j.issn.2096-7993.2022.09.015.

本文引用的文献

1
Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".根治性放化疗在头颈部鳞癌患者中的应用——来自临床合作组“头颈部癌症个体化放疗”的未经选择队列的结果。
Radiat Oncol. 2020 Jan 6;15(1):7. doi: 10.1186/s13014-019-1452-4.
2
Tumor Volume Useful Beyond Classic Criteria in Selecting Larynx Cancers For Preservation Therapy.肿瘤体积在选择喉癌保喉治疗中的经典标准之外仍然有用。
Laryngoscope. 2020 Oct;130(10):2372-2377. doi: 10.1002/lary.28396. Epub 2019 Nov 13.
3
Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suv) In Laryngeal and Hypopharyngeal Cancer.
治疗前最大标准化摄取值(Suv)对喉癌和下咽癌的预测价值。
Sci Rep. 2019 Jun 20;9(1):8972. doi: 10.1038/s41598-019-45462-y.
4
Rational choice of induction chemotherapy-based larynx preservation for hypopharyngeal cancer.下咽癌基于诱导化疗的喉保留术的合理选择
Acta Otolaryngol. 2018 Dec;138(12):1146-1153. doi: 10.1080/00016489.2018.1506152. Epub 2019 Jan 21.
5
Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography evaluation using metabolic tumor volume of the primary tumor and lymph nodes in advanced hypopharyngeal cancer.原发肿瘤和淋巴结的 18F-氟脱氧葡萄糖正电子发射断层扫描评估的代谢肿瘤体积在晚期下咽癌中的预后意义。
Head Neck. 2019 Mar;41(3):739-747. doi: 10.1002/hed.25429. Epub 2018 Dec 7.
6
Metabolic tumor volume of primary tumor predicts survival better than T classification in the larynx preservation approach.在喉保留治疗方法中,原发肿瘤的代谢肿瘤体积比T分类更能预测生存率。
Cancer Sci. 2017 Oct;108(10):2030-2038. doi: 10.1111/cas.13345. Epub 2017 Aug 30.
7
Relationship between response to induction chemotherapy and disease control in patients with advanced laryngeal carcinoma included in an organ preservation protocol.纳入器官保留方案的晚期喉癌患者诱导化疗反应与疾病控制之间的关系。
Eur Arch Otorhinolaryngol. 2017 Jun;274(6):2581-2587. doi: 10.1007/s00405-017-4548-1. Epub 2017 Mar 27.
8
Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and F-FDG-PET/CT.晚期喉癌和下咽癌喉功能保留的诱导化疗后放疗:基于临床评估、CT容积测量和F-FDG-PET/CT评分对一周期诱导化疗后的疗效预测
Eur J Cancer. 2017 Feb;72:144-155. doi: 10.1016/j.ejca.2016.11.013. Epub 2016 Dec 26.
9
Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors.基于诱导化疗的局部晚期下咽癌喉保留方案:肿瘤学和功能结局及预后因素
Eur Arch Otorhinolaryngol. 2016 Oct;273(10):3299-306. doi: 10.1007/s00405-016-3919-3. Epub 2016 Feb 9.
10
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.诱导化疗联合顺铂、5-氟尿嘧啶、±多西他赛用于喉保留的多中心随机 III 期试验的长期结果。
J Natl Cancer Inst. 2015 Dec 16;108(4). doi: 10.1093/jnci/djv368. Print 2016 Apr.